Exciting News Cryoablation, a groundbreaking treatment for early-stage breast cancer, is proving to be a game-changer for older women!
Our very own Dr. Richard Fine presented remarkable findings at The American Society of Breast Surgeons annual meeting.
KEY HIGHLIGHTS:
Study Results: After a 5-year follow-up, the study showed a low ipsilateral breast tumor recurrence rate of 4.3%, with a high breast cancer survival rate of 96.7% and an overall survival rate of 88.6%.
Dr. Richard Fine: Leading the charge, Dr. Fine emphasized the importance of cryoablation as a safe alternative for women over 60, especially when surgery might not be feasible.
Minimal Risks: No serious device-related adverse events were reported, with only minor side effects such as bruising and localized edema.
Patient Satisfaction: Remarkably, 100% of patients and physicians reported satisfaction with the cosmetic results, underlining the success of this innovative approach.
Important Note: While cryoablation hasn’t been FDA-approved for breast cancer yet, it’s showing immense promise in clinical trials. Dr. Fine suggests its use should be limited to clinical trial settings until further approval.This study brings so much hope for a less invasive treatment option for early-stage breast cancer. Thank you, Dr. Richard Fine and your team, for this groundbreaking work!